<DOC>
	<DOCNO>NCT00372632</DOCNO>
	<brief_summary>The present study address question whether use IPT use SP pregnancy efficacious Rwanda , go use first time , area high level SP resistance . While implementation new policy take place area low SP resistance level , expect pregnant woman newborn benefit , paramount importance clarify real impact IPT/SPin area high SP drug resistance level SP resistance strategy still efficacious . As bed net part actual control strategy malaria pregnancy woman receive bed net enrolment</brief_summary>
	<brief_title>IPT Malaria With SP Different Zones Drug Resistance Rwanda</brief_title>
	<detailed_description>The present study address question whether use IPT use SP pregnancy efficacious Rwanda , go use first time , area high level SP resistance . While implementation new policy take place area low SP resistance level , expect pregnant woman newborn benefit , paramount importance clarify real impact IPT/SPin area high SP drug resistance level SP resistance strategy still efficacious . As bed net part actual control strategy malaria pregnancy woman receive bed net enrolment . This randomize blind placebo control trial : woman 16-28th week gestation offer enrolment study randomize receive IPT/SP regimen placebo second third trimester . The study conduct Mashesha ( estimate SP drug resistance 20 % , 12 % 2000 ) , Kicukiro ( 40 % SP resistance ) Rukara ( 60 % SP resistance ) . In site 1000 delivery per year . According DHMT data , 75 % pregnant woman attend antenatal clinic , usually book 15 25 week gestation . Based study expect find placental malaria prevalence 50 % site .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>1 . Pregnant woman 1628 week gestation ; 2 . Residence within catchment 's area health facility ; 3 . Willing deliver health facility ; 4 . Willing ; adhere requirement study ; 5 . Willing provide write informed consent ; 6 . Aged 21 year 1 . Severe anemia ( Hb &lt; 6 g/dL ) 2 . History allergic reaction sulfa drug ; 3 . Taking sulfa drug CTX ; 4 . History known pregnancy complication ( e.g . breech presentation , severe preeclampsia , prior caesarian section ) ; 5 . History presence major illness likely influence pregnancy outcome include diabetes mellitus , severe renal heart disease , active tuberculosis , prior randomization ; 6 . Any significant illness require hospitalization ; 7 . Intent move study catchment 's area delivery deliver relative 's home catchment 's area ; 8 . Prior enrollment study concurrent enrollment another study</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pregnancy malaria prevention</keyword>
</DOC>